Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-AnalysisFrancesco Del Giudice, Ettore De Berardinis, Marco Moschini et al.|Cancers|2023Cited by 28
Surgical checklist adherence across urology expertise levels impacts transurethral resection of bladder tumour quality indicatorsFrancesco Del Giudice, Francesco Soria, David D‘Andrea et al.|British Journal of Urology|2022Cited by 15
Outcomes of <scp>BCG</scp> vs upfront radical cystectomy for high‐risk non‐muscle‐invasive bladder cancerPietro Scilipoti, Marco Moschini, Mattia Longoni et al.|British Journal of Urology|2025Cited by 12
Prognosis of patients with T1 low-grade urothelial bladder cancer treated with bacillus Calmette-Guérin immunotherapyRadosław Piszczek, Tomasz Szydełko, Wojciech Krajewski et al.|Minerva Urology and Nephrology|2023Cited by 9
Cisplatin eligibility in the neoadjuvant setting of patients with muscle-invasive bladder cancer undergoing radical cystectomyRenate Pichler, Laura S. Mertens, Josef Fritz et al.|The Oncologist|2024Cited by 9